Universitätsklinikum Tübingen — Klinik für Psychiatrie und Psychotherapie
Tübingen, Germany
Treatment & access
- Treatments offeredLSD (MM120 — clinical trial)
- Access routeTrial
- Cost & coverage (registry status)Free within clinical trial
- Websitehttps://www.medizin.uni-tuebingen.de
Related listings
These records belong to the same organisation. They are listed separately because each is a distinct programme or location.
- Location in TuebingenUniversitaetsklinikum Tuebingen AöR — Clinical trials
About this provider
Universitätsklinikum Tübingen — Klinik für Psychiatrie und Psychotherapie in Tübingen, Germany, is listed as a site of the Panorama study, a Phase 3 clinical trial of MM120 (lysergide, a pharmaceutical form of LSD) in generalized anxiety disorder, registered on ClinicalTrials.gov under NCT06809595, the registry source cited by this record. As of 2026-08-07 the registry lists the study as ACTIVE_NOT_RECRUITING: recruitment has closed and new participants can no longer join at this site. Within the trial, treatment is free of charge for enrolled participants. The record was last verified on 2026-08-07.
Verification
- License / registryCTIS (EU Clinical Trials Information System)
- Official registryhttps://euclinicaltrials.eu/ctis-public/view/2024-513572-17-00
- Official registryhttps://clinicaltrials.gov/study/NCT06809595
- Provider websitehttps://www.medizin.uni-tuebingen.de
- Last verified
Check your fit & enquire
Clinical trials access in Germany follows published criteria. A short pre-screening comes first — then your compiled summary goes to Universitätsklinikum Tübingen — Klinik für Psychiatrie und Psychotherapie only with your explicit consent, and you can download it for yourself either way.
Check my fit & enquire